



Socioeconomic

Population¹

26,498.82 (2024)

Life expectancy at birth¹

74.5 years (2024)

GDP/capita (current US\$)¹

US\$ 1457 (2023)




Spending on health

Current health expenditure
(CHE)/capita (current US\$)

No data

No data

Current health
expenditure as share
of GDP

7.1% (2020)

Government health
expenditure (% of CHE)¹No data
Out-of-pocket
expenditure (% of CHE)

Spending on pharmaceuticals

Government pharmaceutical
expenditure

No data

No data

Pharmaceutical
expenditure (% of CHE)⁵

No data

Share of out-of-pocket
expenditure on
pharmaceuticals⁶Government pharmaceutical
expenditure/capita

No data



Medical and pharmacy workforce

Medical doctors/
10 000 population¹

38.42 (2022)

Pharmacists/
10 000 population¹

4.04 (2022)

Pharmacy education
accreditation

No data

Continuing professional
development for pharmacists

No data

Pharmaceutical legislation and policy¹

2016

National Legislation, Rule and Regulations for Narcotic Control (revived)

2018

National Pharmaceutical Legislation - 8th edition

2018–2020

National Action Plan on AMR

2021

Law and Regulation on Narcotic Control

2022

Law and Regulation on Narcotic Control; Law and Regulation on Medicine Management

2022–2024

National Action Plan on AMR



Intellectual property rights



TRIPS flexibilities
incorporated into
the law



TRIPS flexibilities
utilized

No data



Rational use and antimicrobial resistance

% of market share of
non-EML products

No data

WHO Global Antimicrobial Resistance and
Use Surveillance System enrollment:
Yes, 2025

Total consumption of antibiotics:
No data

FDC sales in the
private market

No data

Number of antibiotics on the private market

	Total	AWaRe			Not recommended
		Access	Watch	Reserve	
Single drugs			No data		
FDCs			No data		

Market
entryNational Regulatory Authority²

National Drug Regulatory Authority (NDRA)

Website: No data

Staff: No data

Annual budget: No data

Products regulated²

☒ Medicines

☒ Biologicals

☐ Medical
devices

☒ Traditional
medicines

Licensing of establishments

☐ Manufacturers

☐ Importers

☐ Exporters

☐ Wholesellers

☐ Distributors

☐ Retailers

National Medicines Quality Control Laboratory

No data

☐ ISO 17025
certified²

☐ WHO
prequalified²

Rational
selectionBody responsible for selection of medical products¹

Ministry of Public Health

☒ HTA used in the selection process

☐ NEML incorporated AWaRE list

☒ Medicines listed by level of care

☐ Traditional medicines included

National Essential Medicines List (number of active ingredient)¹

2019

300 medicines

National Medicines Formulary

No data

National Essential Diagnostics List: No data

Purchasing



Public sector

☒ Procurement¹: Centralized

Agency responsible for procurement: Ministry of Public Health

LMIS used: No data

Frequency of tender: No data

Private sector

☒ Social Health Insurance

Name of SHI scheme: No data

Population coverage: No data

Number of products covered: No data

Pricing regulation

Pricing regulatory authority¹

National Price Control Committee

Public sector

Tendering: No data

Private sector

Maximum retail price¹: Yes

Number of price controlled products: No data

No data

Market distribution



Estimated pharmaceutical market value

No data

Public

Tertiary hospitals: No data

Secondary hospitals: No data

PHC facilities: No data

Private

Manufacturers: No data

Importers: No data

Wholesellers/distributors: No data

Retail pharmacies: No data

Market exit



Legal provision for

☒ Cancellation of licences of pharmaceutical establishments

☒ Cancellation of marketing authorization of products

☒ Initiating product recalls and withdrawals

References

1. Reported by Ministry of Public Health (internal communication)
2. World Health Organization, Regional Office for South-East Asia, Access to medical products in the South-East Asia Region, 2019, <https://www.who.int/publications/i/item/9789290227281>, accessed 25 August 2025.